Mechanism of degrader-targeted protein ubiquitinability
Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanis...
Saved in:
| Published in | Science advances Vol. 10; no. 41; p. eado6492 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
11.10.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4
toward UBE2R1-ubiquitin, and Lys
at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4
, with cellular degradation and ubiquitinomics confirming the importance of Lys
and nearby Lys
/Lys
, identifying the "ubiquitination zone." Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4
for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design. |
|---|---|
| AbstractList | Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4BD2 toward UBE2R1-ubiquitin, and Lys456 at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4BD2, with cellular degradation and ubiquitinomics confirming the importance of Lys456 and nearby Lys368/Lys445, identifying the "ubiquitination zone." Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4BD2 for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design.Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4BD2 toward UBE2R1-ubiquitin, and Lys456 at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4BD2, with cellular degradation and ubiquitinomics confirming the importance of Lys456 and nearby Lys368/Lys445, identifying the "ubiquitination zone." Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4BD2 for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design. Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4 BD2 toward UBE2R1-ubiquitin, and Lys 456 at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4 BD2 , with cellular degradation and ubiquitinomics confirming the importance of Lys 456 and nearby Lys 368 /Lys 445 , identifying the “ubiquitination zone.” Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4 BD2 for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design. PROTAC-targeted protein ubiquitination specificity revealed by structures with cullin RING E3 ligase and E2-ubiquitin. Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously undrugged targets. Stable and long-lived degrader-mediated ternary complexes drive fast and profound target degradation; however, the mechanisms by which they affect target ubiquitination remain elusive. Here, we show cryo-EM structures of the VHL Cullin 2 RING E3 ligase with the degrader MZ1 directing target protein Brd4 toward UBE2R1-ubiquitin, and Lys at optimal positioning for nucleophilic attack. In vitro ubiquitination and mass spectrometry illuminate a patch of favorably ubiquitinable lysines on one face of Brd4 , with cellular degradation and ubiquitinomics confirming the importance of Lys and nearby Lys /Lys , identifying the "ubiquitination zone." Our results demonstrate the proficiency of MZ1 in positioning the substrate for catalysis, the favorability of Brd4 for ubiquitination by UBE2R1, and the flexibility of CRL2 for capturing suboptimal lysines. We propose a model for ubiquitinability of degrader-recruited targets, providing a mechanistic blueprint for further rational drug design. |
| Author | Nakasone, Mark A Hay, Ronald T Ciulli, Alessio Chandler, Sarah Sathe, Gajanan Craigon, Conner Tatham, Michael H Crowe, Charlotte Makukhin, Nikolai |
| Author_xml | – sequence: 1 givenname: Charlotte orcidid: 0000-0003-2068-8255 surname: Crowe fullname: Crowe, Charlotte organization: Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee DD1 5EH, UK – sequence: 2 givenname: Mark A orcidid: 0000-0002-1362-191X surname: Nakasone fullname: Nakasone, Mark A organization: Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee DD1 5EH, UK – sequence: 3 givenname: Sarah surname: Chandler fullname: Chandler, Sarah organization: Division of Molecular, Cellular and Developmental Biology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK – sequence: 4 givenname: Conner surname: Craigon fullname: Craigon, Conner organization: Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, Dundee DD1 5JJ, UK – sequence: 5 givenname: Gajanan orcidid: 0000-0002-6239-5365 surname: Sathe fullname: Sathe, Gajanan organization: Centre for Targeted Protein Degradation, School of Life Sciences, University of Dundee, 1 James Lindsay Place, Dundee DD1 5JJ, UK – sequence: 6 givenname: Michael H surname: Tatham fullname: Tatham, Michael H organization: Division of Molecular, Cellular and Developmental Biology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK – sequence: 7 givenname: Nikolai orcidid: 0000-0003-2465-0748 surname: Makukhin fullname: Makukhin, Nikolai organization: Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee DD1 5EH, UK – sequence: 8 givenname: Ronald T orcidid: 0000-0001-7113-9024 surname: Hay fullname: Hay, Ronald T organization: Division of Molecular, Cellular and Developmental Biology, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK – sequence: 9 givenname: Alessio orcidid: 0000-0002-8654-1670 surname: Ciulli fullname: Ciulli, Alessio organization: Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, James Black Centre, Dow Street, Dundee DD1 5EH, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39392888$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkLtOw0AQRVcoiISQlhK5pHHYh72PEkUEkIJooLbGu-OwyI9k10bK32OUgKhminPvjM4lmbRdi4RcM7pkjMu7aD24ryW4TmaGn5EZFypPeZ7pyb99ShYxflJKWSZlzswFmQojDNdaz4h6QfsBrY9N0lWJw20AhyHtIWyxR5fsQtejb5Oh9PvB976F0te-P1yR8wrqiIvTnJP39cPb6indvD4-r-43qeWc9qm0qMpS29LieI4KzrVk3BkAgS4TCNLoSlkLZYYCEJ0Ep5STCgSnVhkxJ7fH3vGR_YCxLxofLdY1tNgNsRCM5WosMXpEl0fUhi7GgFWxC76BcCgYLX58FUdfxcnXGLg5dQ9lg-4P_7UjvgFJTWsW |
| Cites_doi | 10.1007/s00249-021-01513-9 10.1002/cmdc.202300464 10.1146/annurev-pharmtox-022123-104147 10.1038/nchembio.2329 10.1038/s41589-018-0055-y 10.1016/j.chembiol.2017.09.010 10.1038/s41392-022-00966-4 10.1126/science.aab1433 10.1002/anie.202109237 10.1039/D2CS00116K 10.1016/j.jsb.2021.107702 10.1038/s41467-021-27210-x 10.1038/s41592-020-00990-8 10.1016/j.chembiol.2021.05.005 10.1093/nar/gkab1174 10.1038/nature13527 10.1038/s41467-023-42233-2 10.1038/nature01456 10.1016/j.cell.2008.07.022 10.1038/s41589-019-0294-6 10.1021/acs.jmedchem.0c01845 10.1177/2472555220965528 10.1016/j.molcel.2021.01.023 10.1016/j.gpb.2022.11.008 10.1038/s41467-022-33575-4 10.1039/C8RA10436K 10.1016/bs.mie.2018.11.005 10.1021/acschembio.8b00692 10.1016/j.str.2017.04.009 10.1038/s41598-021-90770-x 10.1038/nsmb.2874 10.1074/jbc.274.17.12036 10.1146/annurev-biochem-090120-013613 10.1016/j.str.2014.12.014 10.1038/s41592-019-0575-8 10.1038/s41592-023-01853-8 10.1128/MCB.00097-16 10.1042/EBC20170041 10.1021/acscentsci.0c00049 10.1038/nature11376 10.1002/pro.4792 10.1016/j.molcel.2008.08.021 10.1146/annurev-biochem-060815-014922 10.1038/s41592-020-01049-4 10.1021/acschembio.5b00216 10.1021/acschembio.9b00092 10.1038/s41573-021-00245-x 10.1038/nbt.1511 10.1002/cmdc.202200615 10.1038/s41467-023-44237-4 10.1038/nprot.2006.468 10.1016/j.molcel.2024.01.022 10.1146/annurev-biochem-032620-104421 10.1016/j.cell.2008.09.049 10.1126/science.aar5839 10.1038/s41467-018-08027-7 10.1038/s41586-020-2000-y 10.1038/nmeth.4169 10.1038/s41586-021-03197-9 10.1038/nchembio.1858 10.1021/jacs.2c10784 10.1038/s41589-021-00878-4 10.1038/s41592-021-01220-5 10.1038/s41589-021-00952-x 10.1002/anie.201914396 10.1016/j.cell.2009.10.030 10.1038/s41586-020-2374-x 10.1016/j.molcel.2009.01.011 10.1039/D2CS00387B 10.1038/s41586-024-07089-6 10.1038/s41589-022-01177-2 10.1093/bioinformatics/btp033 10.1038/s42003-019-0437-z 10.1038/s41594-023-01206-1 10.1038/s41573-021-00371-6 10.1038/s41467-023-39904-5 10.1002/pro.4176 10.1038/s41571-023-00736-3 10.1016/S1097-2765(03)00452-0 10.1038/s41594-023-01146-w 10.1073/pnas.1407849111 10.1016/j.molcel.2010.02.025 10.1016/j.jmb.2015.09.014 10.1016/j.jbc.2022.101653 10.1007/978-1-0716-1665-9_5 10.1021/acs.jmedchem.1c00895 10.1107/S2059798318002425 10.1021/bi101913m 10.1016/j.str.2013.02.019 10.1093/nar/gkh340 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
| DOI | 10.1126/sciadv.ado6492 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Sciences (General) |
| EISSN | 2375-2548 |
| ExternalDocumentID | 10_1126_sciadv_ado6492 39392888 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS AAFWJ ACGFS ADAXU ADBBV ADPDF AENVI AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BBORY BCGUY BCNDV BKF CGR CUY CVF EBS ECM EIF FRP GROUPED_DOAJ HYE KQ8 M48 M~E NPM OK1 OVD OVEED RHF RHI RPM TEORI AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c220t-6ce7bb8cbce88803228612d9aa3ed43ea698f7ccab4e3aeed6ad77d67a320c793 |
| IEDL.DBID | M48 |
| ISSN | 2375-2548 |
| IngestDate | Sat Oct 26 01:55:00 EDT 2024 Fri Dec 06 07:14:37 EST 2024 Sat Nov 02 12:25:20 EDT 2024 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 41 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c220t-6ce7bb8cbce88803228612d9aa3ed43ea698f7ccab4e3aeed6ad77d67a320c793 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2465-0748 0000-0003-2068-8255 0000-0002-1362-191X 0000-0002-8654-1670 0000-0002-6239-5365 0000-0001-7113-9024 |
| OpenAccessLink | https://doi.org/10.1126/sciadv.ado6492 |
| PMID | 39392888 |
| PQID | 3115769898 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3115769898 crossref_primary_10_1126_sciadv_ado6492 pubmed_primary_39392888 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-Oct-11 2024-10-11 20241011 |
| PublicationDateYYYYMMDD | 2024-10-11 |
| PublicationDate_xml | – month: 10 year: 2024 text: 2024-Oct-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Science advances |
| PublicationTitleAlternate | Sci Adv |
| PublicationYear | 2024 |
| References | e_1_3_2_26_2 e_1_3_2_49_2 e_1_3_2_28_2 e_1_3_2_41_2 e_1_3_2_64_2 e_1_3_2_87_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_62_2 e_1_3_2_85_2 e_1_3_2_22_2 e_1_3_2_45_2 e_1_3_2_68_2 e_1_3_2_24_2 e_1_3_2_47_2 e_1_3_2_66_2 e_1_3_2_89_2 e_1_3_2_60_2 e_1_3_2_83_2 e_1_3_2_81_2 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_54_2 e_1_3_2_75_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_52_2 e_1_3_2_73_2 e_1_3_2_5_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_58_2 e_1_3_2_79_2 e_1_3_2_3_2 e_1_3_2_14_2 e_1_3_2_35_2 e_1_3_2_56_2 e_1_3_2_77_2 e_1_3_2_50_2 e_1_3_2_71_2 e_1_3_2_90_2 e_1_3_2_27_2 e_1_3_2_48_2 e_1_3_2_29_2 e_1_3_2_40_2 e_1_3_2_65_2 e_1_3_2_86_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_63_2 e_1_3_2_84_2 e_1_3_2_23_2 e_1_3_2_44_2 e_1_3_2_69_2 e_1_3_2_25_2 e_1_3_2_46_2 e_1_3_2_67_2 e_1_3_2_88_2 e_1_3_2_61_2 e_1_3_2_82_2 e_1_3_2_80_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_17_2 e_1_3_2_59_2 e_1_3_2_6_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_53_2 e_1_3_2_76_2 e_1_3_2_32_2 e_1_3_2_51_2 e_1_3_2_74_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_57_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_55_2 e_1_3_2_78_2 e_1_3_2_2_2 e_1_3_2_91_2 e_1_3_2_72_2 e_1_3_2_70_2 |
| References_xml | – ident: e_1_3_2_86_2 doi: 10.1007/s00249-021-01513-9 – ident: e_1_3_2_12_2 doi: 10.1002/cmdc.202300464 – ident: e_1_3_2_20_2 doi: 10.1146/annurev-pharmtox-022123-104147 – ident: e_1_3_2_14_2 doi: 10.1038/nchembio.2329 – ident: e_1_3_2_18_2 doi: 10.1038/s41589-018-0055-y – ident: e_1_3_2_35_2 doi: 10.1016/j.chembiol.2017.09.010 – ident: e_1_3_2_2_2 doi: 10.1038/s41392-022-00966-4 – ident: e_1_3_2_10_2 doi: 10.1126/science.aab1433 – ident: e_1_3_2_37_2 doi: 10.1002/anie.202109237 – ident: e_1_3_2_19_2 doi: 10.1039/D2CS00116K – ident: e_1_3_2_62_2 doi: 10.1016/j.jsb.2021.107702 – ident: e_1_3_2_33_2 doi: 10.1038/s41467-021-27210-x – ident: e_1_3_2_81_2 doi: 10.1038/s41592-020-00990-8 – ident: e_1_3_2_44_2 doi: 10.1016/j.chembiol.2021.05.005 – ident: e_1_3_2_58_2 doi: 10.1093/nar/gkab1174 – ident: e_1_3_2_16_2 doi: 10.1038/nature13527 – ident: e_1_3_2_71_2 doi: 10.1038/s41467-023-42233-2 – ident: e_1_3_2_72_2 doi: 10.1038/nature01456 – ident: e_1_3_2_50_2 doi: 10.1016/j.cell.2008.07.022 – ident: e_1_3_2_36_2 doi: 10.1038/s41589-019-0294-6 – ident: e_1_3_2_38_2 doi: 10.1021/acs.jmedchem.0c01845 – ident: e_1_3_2_21_2 doi: 10.1177/2472555220965528 – ident: e_1_3_2_66_2 doi: 10.1016/j.molcel.2021.01.023 – ident: e_1_3_2_68_2 doi: 10.1016/j.gpb.2022.11.008 – ident: e_1_3_2_34_2 doi: 10.1038/s41467-022-33575-4 – ident: e_1_3_2_78_2 doi: 10.1039/C8RA10436K – ident: e_1_3_2_75_2 doi: 10.1016/bs.mie.2018.11.005 – ident: e_1_3_2_41_2 doi: 10.1021/acschembio.8b00692 – ident: e_1_3_2_13_2 doi: 10.1016/j.str.2017.04.009 – ident: e_1_3_2_74_2 doi: 10.1038/s41598-021-90770-x – ident: e_1_3_2_17_2 doi: 10.1038/nsmb.2874 – ident: e_1_3_2_48_2 doi: 10.1074/jbc.274.17.12036 – ident: e_1_3_2_5_2 doi: 10.1146/annurev-biochem-090120-013613 – ident: e_1_3_2_47_2 doi: 10.1016/j.str.2014.12.014 – ident: e_1_3_2_80_2 doi: 10.1038/s41592-019-0575-8 – ident: e_1_3_2_60_2 doi: 10.1038/s41592-023-01853-8 – ident: e_1_3_2_65_2 doi: 10.1128/MCB.00097-16 – ident: e_1_3_2_27_2 doi: 10.1042/EBC20170041 – ident: e_1_3_2_43_2 doi: 10.1021/acscentsci.0c00049 – ident: e_1_3_2_53_2 doi: 10.1038/nature11376 – ident: e_1_3_2_83_2 doi: 10.1002/pro.4792 – ident: e_1_3_2_56_2 doi: 10.1016/j.molcel.2008.08.021 – ident: e_1_3_2_4_2 doi: 10.1146/annurev-biochem-060815-014922 – ident: e_1_3_2_61_2 doi: 10.1038/s41592-020-01049-4 – ident: e_1_3_2_9_2 doi: 10.1021/acschembio.5b00216 – ident: e_1_3_2_30_2 doi: 10.1021/acschembio.9b00092 – ident: e_1_3_2_67_2 doi: 10.1038/s41573-021-00245-x – ident: e_1_3_2_88_2 doi: 10.1038/nbt.1511 – ident: e_1_3_2_46_2 doi: 10.1002/cmdc.202200615 – ident: e_1_3_2_22_2 doi: 10.1038/s41467-023-44237-4 – ident: e_1_3_2_87_2 doi: 10.1038/nprot.2006.468 – ident: e_1_3_2_70_2 doi: 10.1016/j.molcel.2024.01.022 – ident: e_1_3_2_6_2 doi: 10.1146/annurev-biochem-032620-104421 – ident: e_1_3_2_51_2 doi: 10.1016/j.cell.2008.09.049 – ident: e_1_3_2_85_2 doi: 10.1126/science.aar5839 – ident: e_1_3_2_29_2 doi: 10.1038/s41467-018-08027-7 – ident: e_1_3_2_31_2 doi: 10.1038/s41586-020-2000-y – ident: e_1_3_2_79_2 doi: 10.1038/nmeth.4169 – ident: e_1_3_2_57_2 doi: 10.1038/s41586-021-03197-9 – ident: e_1_3_2_11_2 doi: 10.1038/nchembio.1858 – ident: e_1_3_2_24_2 doi: 10.1021/jacs.2c10784 – ident: e_1_3_2_39_2 doi: 10.1038/s41589-021-00878-4 – ident: e_1_3_2_63_2 doi: 10.1038/s41592-021-01220-5 – ident: e_1_3_2_77_2 doi: 10.1038/s41589-021-00952-x – ident: e_1_3_2_42_2 doi: 10.1002/anie.201914396 – ident: e_1_3_2_55_2 doi: 10.1016/j.cell.2009.10.030 – ident: e_1_3_2_26_2 doi: 10.1038/s41586-020-2374-x – ident: e_1_3_2_49_2 doi: 10.1016/j.molcel.2009.01.011 – ident: e_1_3_2_15_2 doi: 10.1039/D2CS00387B – ident: e_1_3_2_25_2 doi: 10.1038/s41586-024-07089-6 – ident: e_1_3_2_45_2 doi: 10.1038/s41589-022-01177-2 – ident: e_1_3_2_89_2 doi: 10.1093/bioinformatics/btp033 – ident: e_1_3_2_82_2 doi: 10.1038/s42003-019-0437-z – ident: e_1_3_2_69_2 doi: 10.1038/s41594-023-01206-1 – ident: e_1_3_2_7_2 doi: 10.1038/s41573-021-00371-6 – ident: e_1_3_2_40_2 doi: 10.1038/s41467-023-39904-5 – ident: e_1_3_2_52_2 doi: 10.1002/pro.4176 – ident: e_1_3_2_3_2 doi: 10.1038/s41571-023-00736-3 – ident: e_1_3_2_73_2 doi: 10.1016/S1097-2765(03)00452-0 – ident: e_1_3_2_23_2 doi: 10.1038/s41594-023-01146-w – ident: e_1_3_2_54_2 doi: 10.1073/pnas.1407849111 – ident: e_1_3_2_59_2 doi: 10.1016/j.molcel.2010.02.025 – ident: e_1_3_2_91_2 doi: 10.1016/j.jmb.2015.09.014 – ident: e_1_3_2_32_2 doi: 10.1016/j.jbc.2022.101653 – ident: e_1_3_2_28_2 doi: 10.1007/978-1-0716-1665-9_5 – ident: e_1_3_2_8_2 doi: 10.1021/acs.jmedchem.1c00895 – ident: e_1_3_2_84_2 doi: 10.1107/S2059798318002425 – ident: e_1_3_2_64_2 doi: 10.1021/bi101913m – ident: e_1_3_2_76_2 doi: 10.1016/j.str.2013.02.019 – ident: e_1_3_2_90_2 doi: 10.1093/nar/gkh340 |
| SSID | ssj0001466519 |
| Score | 2.3217244 |
| Snippet | Small-molecule degraders of disease-driving proteins offer a clinically proven modality with enhanced therapeutic efficacy and potential to tackle previously... |
| SourceID | proquest crossref pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | eado6492 |
| SubjectTerms | Bromodomain Containing Proteins Cell Cycle Proteins - chemistry Cell Cycle Proteins - metabolism Cryoelectron Microscopy Humans Lysine - chemistry Lysine - metabolism Models, Molecular Protein Binding Proteolysis Transcription Factors - chemistry Transcription Factors - metabolism Ubiquitin - metabolism Ubiquitin-Conjugating Enzymes - chemistry Ubiquitin-Conjugating Enzymes - metabolism Ubiquitination Von Hippel-Lindau Tumor Suppressor Protein - chemistry Von Hippel-Lindau Tumor Suppressor Protein - metabolism |
| Title | Mechanism of degrader-targeted protein ubiquitinability |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39392888 https://www.proquest.com/docview/3115769898 |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS8MwFA4yX3wR53VeRgVBfcjY0ixpHkREHEOYTw72VpImgYK2bm3F_XtP0s4LKvgDEsh3cnq-05zzHYTOrDE8FFJhJ6aG4VIQLKjQmBrXlKatYdr1O08e2HhK72fD2Wf9UwNg8Wtq5-ZJTRdPvbf58hoc_upLA4zUrz2pc0YFfI7XCURFV941aai-_99CGRv6OR8k5EMMeVHUaDj-3OJ7jPqDePoANNpCmw1zDG5qU7fRmsm2UbvxzSK4aASkL3cQnxjXz5sWz0FuA-3kILRZ4Lro2-jAazOkWVCpdF6lpWufchWyy100Hd093o5xMyABJ4T0S8wSw5WKEpUYSGT74JsREBYtpAyNpqGRTESWg40UNaGEaMik5lwzLkPST8Az91AryzNzgIKEJJYwWOAGF8mBFcpKS7WIIqZYxG0Hna8giV9qHYzY5w-ExTV4cQNeB52uEIvhqrr3B5mZvCpiL-zjB1Z20H4N5cdeoQCiBoc4_MfqI7RBgFq4CDIYHKNWuajMCVCDUnV9St31ln8HkXG7MQ |
| link.rule.ids | 314,780,784,864,2221,24318,27924,27925 |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mechanism+of+degrader-targeted+protein+ubiquitinability&rft.jtitle=Science+advances&rft.au=Crowe%2C+Charlotte&rft.au=Nakasone%2C+Mark+A&rft.au=Chandler%2C+Sarah&rft.au=Craigon%2C+Conner&rft.date=2024-10-11&rft.issn=2375-2548&rft.eissn=2375-2548&rft.volume=10&rft.issue=41&rft.spage=eado6492&rft_id=info:doi/10.1126%2Fsciadv.ado6492&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2375-2548&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2375-2548&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2375-2548&client=summon |